AstraZeneca to sell Moventig’s European marketing rights to ProStrakan
ProStrakan agreed to pay AstraZeneca $70m upfront for the rights in the European Union as well as Iceland, Norway, Switzerland, and Liechtenstein. AstraZeneca will also receive future tiered
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.